Shots:

• Astellas to receive ~$88.3M as up front for its three products. Daiichi to get rights and obligations- including manufacturing and marketing approvals for Nasea (ramosetron)- Perdipine (nicardipine) and Oldeca (barnidipine) from Dec’2019
• The focus of the agreement is to strengthen Daiichi’s presence in Asia and to contribute to healthcare in Asia by acquiring two anti-hypertensive and anti-emetic therapies from Astellas
• Nasea is an antiemetic therapy- expected to have synergic effect with Daiichi’s Mirogabalin and the cancer therapies while Perdipine & Oldeca are anti-hypertensive therapies- expected to be utilized in combination with Daiichi’s cardiovascular products- Olmesartan and Edoxaban

Click here to­ read full press release/ article 

Ref:Daiichi Sankyo | Image: Astellas